Structural Reality is a series examining how systems produce unequal outcomes across work, income, and opportunity.
The shift is already underway. At least 18 states have moved to restrict or scale back AIDS Drug Assistance Programs (ADAP), with five more considering similar changes. The programs, funded through the Ryan White HIV/AIDS Program, provide life-saving medication to roughly 300,000 Americans — many of whom rely on them as a last line of access to care. In a country where more than 1.2 million people are living with HIV, what’s changing isn’t the need. It’s the ability to qualify for help.
The pressure is coming from both sides. The cost of HIV medication continues to climb, with widely prescribed treatments now exceeding $60,000 annually. At the same time, more people are being pushed into these programs as Medicaid coverage declines and insurance premiums rise — increasing enrollment by roughly 30% in recent years. Federal funding, however, has remained largely flat, creating a widening gap between cost and coverage. The result is a system that is no longer expanding access, but narrowing it.
The burden is not evenly distributed. Black Americans account for more than 40% of new HIV diagnoses despite representing just 13% of the population — a disparity driven less by individual behavior than by structural conditions that shape access to care. Preventive tools like PrEP, which can reduce the risk of HIV transmission by up to 99% when taken consistently, remain significantly underutilized in Black communities due to cost, access, and awareness gaps. Interruptions in care carry immediate consequences — missed doses increase the risk of drug resistance, limit future treatment options, and raise the likelihood of transmission. What appears as a cost-saving measure at the policy level produces higher downstream costs every time.
This dynamic reflects a pattern we’ve been tracking across both domestic and global coverage — in When Access Becomes Conditional, where eligibility tightening is already reshaping who receives HIV care in the U.S., and in HIV Treatment Didn’t Collapse — But What’s Holding It Up Should Concern You, where volunteer labor is quietly absorbing the cost of a weakening formal system globally. The math is straightforward. Costs are rising. Access is tightening. And the gap between the two is being absorbed by the people least positioned to carry it.
Why It Matters
This is a cost shift disguised as policy. When access to consistent treatment breaks down, the downstream effects become more expensive — not less. Interruptions in medication increase the risk of drug resistance, hospitalizations, and new transmissions, driving up long-term healthcare costs across the system. At the same time, tightening eligibility effectively rations care, pushing the highest burden onto populations already overrepresented in the data. The result is a familiar pattern: short-term savings at the policy level, long-term cost escalation at the system level — with the human impact concentrated where access was already most fragile.